Regencell Bioscience Holdings Ltd
RGC · Medicinal Chemicals & Botanical Products · EDGAR filings ↗
Grade
D44Early-stage TCM developer for ADHD/ASD with no revenue, no patents, and no regulatory filings.
Strengths
- Ample near-term liquidity (current/quick ratio ~7.4, 98th pct) from prior IPO proceeds
- No debt and contained absolute losses (~$3.6M net loss)
Risks
- No approved products, no granted/pending patents, no revenue; deeply negative ROE (-73.7%, 10th pct)
- Founder-controlled Cayman/HK FPI with speculative valuation history and unproven, single-program business model
Notable findings
- Cash burnNegative free cash flow (-3.3M)
Key metrics
Return on equity
-73.7%
Return on assets
-62.3%
Current ratio
7.4×
Free cash flow
-$3M
Tangible book value
$5M
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2025-10-31 | 2025-06-30 | 0001213900-25-104686 ↗ |
| 20-F | 2024-10-25 | 2024-06-30 | 0001213900-24-090791 ↗ |
| 20-F | 2023-10-27 | 2023-06-30 | 0001013762-23-007289 ↗ |
| 20-F | 2022-10-31 | 2022-06-30 | 0001213900-22-067683 ↗ |
| 20-F | 2021-10-29 | 2021-06-30 | 0001213900-21-055256 ↗ |